FTB Advisors Inc. reduced its stake in Henry Schein Inc. (NASDAQ:HSIC) by 11.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 873 shares of the company’s stock after selling 111 shares during the period. FTB Advisors Inc.’s holdings in Henry Schein were worth $154,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in HSIC. Quadrant Capital Group LLC boosted its position in Henry Schein by 0.4% in the second quarter. Quadrant Capital Group LLC now owns 742 shares of the company’s stock worth $128,000 after buying an additional 3 shares during the last quarter. Essex Financial Services Inc. purchased a new position in Henry Schein during the second quarter worth approximately $203,000. Wagner Bowman Management Corp purchased a new position in Henry Schein during the second quarter worth approximately $231,000. Berkshire Asset Management LLC PA purchased a new position in Henry Schein during the second quarter worth approximately $246,000. Finally, Eqis Capital Management Inc. boosted its position in Henry Schein by 23.4% in the second quarter. Eqis Capital Management Inc. now owns 1,639 shares of the company’s stock worth $290,000 after buying an additional 311 shares during the last quarter. Institutional investors and hedge funds own 92.03% of the company’s stock.
Henry Schein Inc. (NASDAQ:HSIC) traded up 0.49% during mid-day trading on Tuesday, hitting $153.96. The company’s stock had a trading volume of 268,592 shares. Henry Schein Inc. has a 12-month low of $142.64 and a 12-month high of $183.00. The firm’s 50-day moving average is $161.88 and its 200-day moving average is $169.89. The company has a market cap of $12.59 billion, a P/E ratio of 26.08 and a beta of 1.05.
Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Thursday, August 4th. The company reported $1.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.01. The firm earned $2.87 billion during the quarter, compared to analyst estimates of $2.85 billion. Henry Schein had a return on equity of 17.84% and a net margin of 4.42%. Henry Schein’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.46 earnings per share. Analysts predict that Henry Schein Inc. will post $6.57 EPS for the current fiscal year.
A number of research firms have recently commented on HSIC. Zacks Investment Research cut Henry Schein from a “hold” rating to a “sell” rating in a research note on Monday. Robert W. Baird cut Henry Schein from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $176.00 to $164.00 in a research note on Friday. Goldman Sachs Group Inc. upgraded Henry Schein from a “neutral” rating to a “buy” rating and set a $185.00 target price for the company in a research note on Tuesday, October 11th. Finally, Bank of America Corp. began coverage on Henry Schein in a research note on Monday, September 12th. They issued a “buy” rating and a $185.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $159.50.
In related news, Director Paul Brons sold 3,381 shares of the business’s stock in a transaction that occurred on Monday, August 29th. The stock was sold at an average price of $164.03, for a total value of $554,585.43. Following the completion of the sale, the director now owns 13,715 shares in the company, valued at $2,249,671.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.27% of the stock is owned by corporate insiders.
Henry Schein Company Profile
Henry Schein, Inc is a provider of health care products and services to office-based dental, animal health and medical practitioners. The Company’s segments include healthcare distribution, and technology and value-added services. The healthcare distribution segment aggregates its global dental, animal health and medical operating segments.
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein Inc. (NASDAQ:HSIC).
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.